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Abstract 248/250 
Introduction 
Syringes with attached needles (low dead space syringes [LDSS]) retain far less blood 
following injection than syringes with detachable needles (high dead space syringes [HDSS]). 
People who inject drugs (PWID) who share needles/syringes may be less likely to acquire 
Hepatitis C virus (HCV) infection using LDSS, compared with HDSS, but data are limited. 
Methods 
Utilising drug behaviour and HCV antibody testing data from the UK 2014/2015 Unlinked 
Anonymous Monitoring Survey of PWID, we calculated the percentage of syringes used in 
the past month that were LDSS. We investigated which injecting characteristics and 
demographic factors were associated with 100% LDSS (against 0-99%) usage, and whether 
100% LDSS use was associated with antibody HCV-status, after adjusting for confounders. 
Result 
Of 2,174 participants, 55% always used LDSS, 27% always used HDSS, and 17% used both 
LDSS and HDSS. PWID that had injected into their groin during the past month were 
unlikely to use LDSS, adjusted odds ratio (aOR) 0.14 (95% confidence interval 0.11-0.17), 
compared to those not using the groin. Those injecting crack were less likely to use LDSS 
than those not, aOR 0.79 (0.63-0.98). Polydrug use was negatively associated with LDSS use, 
aOR 0.88 (0.79-0.98) per additional drug. LDSS use was associated with lower prevalent 
HCV among all PWID (aOR 0.77, [0.64-0.93]), which was stronger among recent initiates 
(aOR 0.53 [0.30-0.94]) than among experienced PWID (aOR 0.81 [0.66-0.99]). 
Discussion 
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People who inject into their groin were less likely to use LDSS. Exclusive LDSS use was 
associated with lower prevalence of HCV amongst PWID that started injecting recently, 
suggesting LDSS use is protective against HCV. 
Key words 
Low dead space syringes, high dead space syringes, safe injecting, injecting drugs, IDU, 
HCV 
Highlights: 
 In the UK, people injecting into their groin were less likely to use low deadspace 
syringes (LDSS) 
 Exclusive use of LDSS was associated with lower HCV prevalence among people 
who inject drugs (PWID) 
 This association was stronger among recent initiates than among experienced PWID 
 Half of the PWID sampled reported always using LDSS 
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Introduction 
People who inject drugs (PWID) are at risk of blood borne viral (BBV) infections through the 
sharing of needles, syringes and other injecting equipment(Corson et al., 2013). As a 
consequence, the prevalence of BBV infections, such as hepatitis C virus (HCV), amongst 
PWID are high(McLauchlan et al., 2017). The high prevalence in this population means that 
prevention efforts to reduce the transmission of BBVs among PWID are important. Although 
evidence is increasing that needle and syringe programmes (NSP) and opiate substitution 
therapy can decrease the risk of HCV acquisition(Platt et al., 2017; Platt et al., 2016; Turner 
et al., 2011; World Health Organization, 2012), modelling suggests they are insufficient to 
reduce HCV to low levels even when there is high coverage(Vickerman et al., 2012), so other 
prevention or treatment strategies are required to further reduce the burden of disease.  
Syringes with attached needles typically have a lower ‘dead space’, and so retain far less 
blood following an injection than syringes that have detachable needles(Binka et al., 2015; 
Grund et al., 1996; Paintsil et al., 2010; Vickerman et al., 2013; Zule et al., 1997), see figure 
1. For PWID that share injecting equipment, using low dead space syringes (LDSS) instead 
of high dead space syringes (HDSS) may lead to a reduced risk of acquiring BBV infections. 
This is because the volume of blood held in a syringe is an important predictor of the viral 
load transmitted, as well as virus survival outside of the body(Abdala et al., 1999). The 
World Health Organization recommends that LDSS are supplied by NSPs to prevent the 
transmission of BBV(World Health Organization, 2012), although evidence for their 
prevention benefit is limited(Ambekar and Pawar, 2013; Gyarmathy et al., 2009; Zule and 
Bobashev, 2009; Zule et al., 2002).  
Research into which subgroups of PWID use LDSS and what factors predict LDSS usage has 
been limited. Awareness of alternatives to HDSS and the inability to successfully access 
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veins have been discussed as possible barriers to LDSS use in face-to-face interviews with 
PWID(Kesten et al., 2017). Some research indicates HDSS with longer needles are required 
for injecting into femoral veins such as those around the groin, and some injectors prefer 
them because they allow replacement of needles during an injection episode, which is needed 
if the needle gets blocked or blunt from repeated attempts to find a vein(Zule et al., 2013; 
Zule et al., 2015).  
In this study, we investigated the characteristics of LDSS users amongst PWID and examined 
whether the type of syringe used was associated with reduced odds of HCV infection in the 
UK. 
 
Methods 
Data 
We used data from the 2014 and 2015 Unlinked Anonymous Monitoring Survey (UAM), an 
annual sero-behavioural survey of PWID recruited from centres providing drug treatment, 
NSPs and outreach work across England, Wales and Northern Ireland, that has been 
described in detail previously(Cullen et al., 2015). Those who agreed to participate were 
asked about their drug use behaviours and demographic information and provided a dried 
blood spot sample that was tested for HCV antibodies (anti-HCV). The study has ethical 
approval. 
Participants were included if they reported injecting in the past month and had a HCV test 
result. Those taking part in 2015 who reported taking part previously in 2014 were excluded 
as repeats. For each participant, we calculated the percentage of syringes used in the past 
month that were LDSS or HDSS based on self-reported use of syringes with either detachable 
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or attached needles from the questions “How many individual needles (including ones 
attached to syringes) did you get from Needle Exchanges during the last month (28 days)?”, 
“How many of these needles were already attached to syringes (barrels)?” these question 
versions were introduced into the survey in 2014. LDSS with detachable needles were rare in 
the UK at the time of these surveys as they had not been introduced by NSPs during this 
period(Abdala et al., 2016). Needles received from NSPs should cover almost all needles 
received in the UK, as public health funded NSPs are widely available throughout the UK, 
and over the counter sales of needles are restricted. We excluded participants without 
information on LDSS use. We used multiple imputation by chained equations to account for 
missing data in covariates, using five imputed datasets. Stata 14.2 statistical software was 
used to analyse the data.  
Statistical methods 
Characteristics of LDSS users 
We tabulated demographic information and reported drug use behaviours against the 
proportion of syringes used that were LDSS in the past 28 days, with this grouped into 0-
99%, and 100% LDSS use.  
 
To investigate which subgroups of PWID used LDSS all the time (throughout the last 
month), we used logistic regression to estimate the unadjusted odds ratio (OR), with 95% 
confidence intervals (CI), of 100% LDSS (against 0-99%) usage by the following variables: 
location (with London region as the comparator); age; gender; years since first injection; days 
injecting past month; type of drug injected in the past month (individual variables for: heroin, 
methadone, crack, cocaine, speed, ketamine, mephedrone, “other drug”); whether they 
injected into their groin in the past the month (versus not injecting into their groin); whether 
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they had been homeless in the past year; whether they had ever received used works from 
anyone; whether they had shared any injecting equipment (needles/syringes/spoons/filter) 
during the past month; whether they had ever been in prison; and polydrug use (an integer 
between 1 and 8, OR per unit increase in types of drug used) 
 
We used multivariable logistic regression with backwards selection of predictors, using an 
alpha of 0.05, to estimate the adjusted odds ratio (aOR), with 95% CI, for 100% LDSS 
(against 0-99%) usage, including the variables listed above, except for polydrug use. We did 
a separate analysis including all variables except the individual drug variables, which were 
replaced by polydrug use. 
 
We included in the multivariable model variables that were selected in the majority of the 
backwards stepwise regressions in the imputed datasets. Estimates were aggregated across the 
imputed datasets using Rubin’s rules(Sterne et al., 2009).  
 
LDSS usage and HCV infection 
 
We used logistic regression to estimate the unadjusted and adjusted association of 100% 
LDSS use, compared to any HDSS use, with prevalent anti-HCV. Variables assessed for 
inclusion in the adjusted model were groin injecting, injecting crack in the past month, 
injecting heroin past month, injecting “other drugs” past month, years since first injection, 
any equipment or syringe sharing in the past month, injection frequency (number of days 
injected past month multiplied by the frequency of injecting on the last day they injected), 
ever been to prison, and homelessness in the previous year.  
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As injecting in the groin requires longer needles that are usually HDSS(Kesten et al., 2017), 
groin injecting and HDSS usage were highly correlated, with both potentially being risk 
factors for HCV infection as groin injecting is associated with other risky behaviours(Rhodes 
et al., 2006). We did not include groin injecting as a confounder in the multivariable model 
because of this collinearity and the possibility that it is on the causal pathway. We repeated 
the analysis adjusting for polydrug use, instead of adjusting for crack, heroin, and “other” 
drug use.   
 
Many of the prevalent HCV infections will have occurred in the past, potentially many years 
ago; it is therefore likely that some behaviours measured by the survey will not be 
representative of the behaviours at the time of infection. We therefore fitted a model that 
included an interaction term between LDSS use and whether a PWID recently started 
injecting – defined as less than 3 years ago. In a sensitivity analysis, we varied the threshold 
for the definition of recently initiating injecting from 2 to 10 years to examine how recency of 
initiation influenced the association between LDSS usage and HCV prevalence.  
 
Results 
Demographics and injecting characteristics 
Of 3,083 surveyed individuals who had injected in the previous month, 909 (28%) were 
excluded as they had missing information on LDSS use. Compared to included PWID, those 
excluded were similar in age, a similar proportion had ever been imprisoned, and a slightly 
higher proportion were females. Of those 2,174 participants with information on LDSS use 
over the past month, 55% always used LDSS, 17% used both LDSS and HDSS, and 27% 
always used HDSS (table 1). Almost all (98%) participants that injected in the previous 
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month responded to the question about injecting into the groin, with 32% reporting they had 
done so. 
Amongst the PWID analysed, 90% had injected heroin in the past month, and of the 10% 
who had not injected heroin, 72% had injected amphetamine (speed). The median age was 37 
years, 24% were female, and 95% were born in the UK. The mean number of days injected in 
the previous month was 17 (median 16) and the mean time since first injection was 15 years 
(median 15). Just over half (55%, 1,191) tested positive for HCV antibodies.  
Predictors of LDSS usage 
Table 1 shows cross tabulations of LDSS usage in last month by demographic and injecting 
characteristics. LDSS usage varied by geographical region, table 2. The highest proportion of 
participants that only used LDSS in the past month was from the West Midlands (68%), with 
London second highest at 66%, and the East Midlands the lowest at 45%. Exclusive LDSS 
use was reported by PWID regardless of years since first injection, although it was more 
common in those who had been injecting for fewer years (supplementary figure 1λ). 
Otherwise, HDSS and LDSS users have similar characteristics except for previous 
imprisonment, crack injecting, and injecting into the groin. Two-thirds (66%) of PWID that 
always used LDSS had ever been to prison, compared to 77% of PWID that used HDSS. 
Injecting crack during the last month was more common in HDSS users, compared with those 
who always used LDSS (47% versus 39%). Injecting into the groin during the last month was 
strongly associated with HDSS use (64% and 20% injected into the groin amongst those who 
had used HDSS or only used LDSS, respectively).  
Predictors of 100% LDSS usage included geographic region, type of drug injected and 
injection site (table 3). Compared to not injecting that drug, injecting crack was predictive of 
not using LDSS, (aOR 0.79 [0.63-0.98]), as was injecting “other drugs” (aOR 0.63 [0.42-
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0.95]), whereas injecting heroin was predictive of using LDSS (aOR 1.47 [1.04-2.08]). Those 
injecting into the groin were very unlikely to use LDSS, aOR 0.14 (0.11-0.17), compared to 
those not injecting into the groin. Selection of variables was consistent over the imputed 
datasets (supplementary table 1λ). In the analysis including polydrug use instead of the 
individual drug variables, we found that polydrug use was negatively associated with 100% 
LDSS use, with an aOR of 0.88 (0.79-0.98) per each additional type of drug injected. 
LDSS usage and HCV infection 
Overall, the HCV prevalence amongst PWID included in the analyses was 55% (53%-57%), 
with it being lower amongst those only using LDSS (50% [47%-53%]) compared to those 
using HDSS (61% [58%-64%]). The proportion with anti-HCV also increased with years 
since first injection and was consistently lower amongst PWID using LDSS across all 
injecting durations (figure 2).  
Compared to any HDSS use, exclusive LDSS use during the last month was associated with 
lower odds of having anti-HCV (table 4, OR 0.64 [0.54-0.76]). In the model adjusted for 
confounders, years since first injection, sharing injecting equipment, injecting crack, and 
having been to prison were all associated with increased odds of having anti-HCV 
(supplementary table 2λ), whereas exclusive LDSS use was associated with lower odds of 
having anti-HCV [aOR 0.77 (0.64-0.93)] when compared with any HDSS use, table 4. 
Polydrug use was associated with increased odds of having HCV (unadjusted OR 1.46 (1.31-
1.62) and adjusted OR 1.38 (1.23-1.55) per additional type of drug. However, the aOR for 
100% LDSS use (vs 0-99%) on HCV remained unchanged. 
Among PWID that had reported starting injecting more recently, exclusive LDSS use was 
associated strongly with lower odds of prevalent anti-HCV. Supplementary figure 2λ shows 
the magnitude of the association was greater when the duration threshold used to define 
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recent initiation was shorter. Amongst those who had injected for less than 3 years, the OR of 
anti-HCV was 0.46 (0.26, 0.80) for exclusive LDSS use compared to any HDSS use (table 
5a), which attenuated to 0.53 (0.30, 0.95) after adjusting for other variables. In the model 
adjusted for confounders, years since first injection, sharing injecting equipment, injecting 
crack, and having been to prison were all associated with increased odds of anti-HCV 
infection (supplementary table 3λ). Although groin injecting was strongly associated with 
anti-HCV prevalence (OR 2.35 [1.96-2.81]), the effect of LDSS on anti-HCV prevalence was 
independent of this association in those who started injecting recently and were therefore less 
likely to inject in the groin. Table 5b also presents the aOR for exclusive LDSS use for PWID 
that had not started injecting recently (>3 years), 0.81 (0.66, 0.99), compared with those who 
had started injecting more recently and used HDSS. This shows that the association between 
exclusive LDSS use and lower odds of anti-HCV seen amongst all PWID is stronger among 
those who had started injecting more recently. 
Discussion  
Main findings 
Among all PWID, 100% LDSS use during the last month was associated with reduced risk of 
HCV infection, with this association being stronger amongst recent initiates (injecting less 
than 3 years). During this period recent behaviours are probably more representative of the 
behaviours when infection occurred. Half of the PWID sampled reported always using LDSS 
and a quarter always used HDSS, which was more common among those injecting into their 
groin or injecting crack or polydrug users. The association with groin injecting is probably 
related to larger needles being needed when injecting into the femoral vein. Patterns of LDSS 
use also varied by geographic region, which may reflect differences in LDSS availability or 
other factors such as what drugs are injected or local preferences.  
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When considering the association between LDSS and HCV infection, it is important to note 
the relationship between these variables and groin injecting. Groin injecting may be a more 
robust marker of HDSS usage than using questions on the type of syringe use because the 
latter was less frequently recorded – 98% of participants that injected in the past month 
answered the groin injecting question, but only 71% answered both questions used to derive 
the LDSS variable. Groin injecting, due to the preferred size of the needle for this injection 
site, was strongly correlated with HDSS use, as also found by other studies(Kesten et al., 
2017). However, some research suggests that people who inject into the groin also engage in 
more risky injection practices that could lead to HCV infection(Rhodes et al., 2006). As 
people in our study who inject into the groin were the main users of HDSS needles and were 
long-term injectors, we only found an independent effect of LDSS usage on HCV infection 
when analyses were stratified by recency of initiating injecting. 
Comparisons with other literature 
To our knowledge this is the first quantitative study measuring LDSS use in the UK. 
However, comparisons with studies from other settings are restricted due to the variety of 
questions used to capture information about syringe use. Whilst we found that 55% of UK 
PWID were currently only using LDSS, studies from Texas, Hungary and Tajikistan found 
much higher levels of LDSS use, although these studies did not necessarily capture 
behaviours within the past month(Gyarmathy et al., 2009; Zule et al., 2002; Zule et al., 2015). 
Elsewhere, other studies from North Carolina, USA, and Tijuana, Mexico, found about 40% 
of PWID had ever used HDSS(Rafful et al., 2015; Zule and Bobashev, 2009). The variation 
in findings is unsurprising given the geographic diversity of these studies, although they do 
suggest that PWID in the UK may have higher use of HDSS than other settings.  
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Regarding reasons for why LDSS or HDSS are used, a recent qualitative study from Bristol, 
UK, found an important motivation behind syringe choice was to inject successfully, with 
changes in syringe use only being considered when problems were encountered(Kesten et al., 
2017). We did not have information on why individuals used HDSS or LDSS but were able 
to examine associations between drug use behaviours and what type of syringe was used. The 
study in Texas found that LDSS use varied by ethnicity – a variable not recorded in our data, 
and HDSS increased with years since first injection, which we also found(Zule et al., 2002). 
In the study from North Carolina, 62% of PWID reporting HDSS use said they did so 
because they were easier to obtain(Zule and Bobashev, 2009). The study in Tijuana found 
that HDSS use was mostly because no other syringe type was available, and that it was 
associated with cocaine use and having been stopped or arrested by police(Rafful et al., 
2015). Data from North Carolina, USA, and Russia showed that HDSS use was associated 
with the use of nonmedical prescription opioids(Zule and Bobashev, 2009; Zule et al., 2016), 
similar to our finding that LDSS use varies according to the drug injected. Lastly, the study 
from Tajikistan found that choice of needle length was influenced by the depth of the vein 
being used, so HDSS were sometimes preferred as the user could select the needle 
length(Zule et al., 2015). This supports our study finding that HDSS use was preferred 
amongst those injecting into the groin.  
There has been limited research into whether the odds of exposure to HCV infection or other 
blood borne viruses is related to the type of syringe used by PWID. The Texan study found 
the proportion of PWID with HIV was higher in those that had ever used HDSS(Zule et al., 
2002). Similarly, the North Carolina study found increased HIV and HCV prevalence with 
increased HDSS use(Zule and Bobashev, 2009), whereas the study from Hungary did not find 
an association with HCV prevalence(Gyarmathy et al., 2009). Our data adds to these studies, 
with our analyses adding more rigour by controlling for other determinants of HCV infection. 
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There are no studies sufficiently powered to estimate the effect of LDSS usage on incident 
HCV or HIV infection. The dataset used in this study test for biological markers of recent 
HCV infection(Cullen et al., 2015), but due to issues with power resulting from incident 
HCV being comparatively rare we were unable to analyse them. 
Strengths and limitations 
Strengths of our study include the relatively large and geographically diverse sample, which 
is likely to be a representative subsample of UK PWID. The wide availability of the NSPs in 
the UK, combined with the restriction on over the counter sales means that NSP provided 
needles (those considered in this study) should account for the vast majority of needles 
received in the UK. Another strength of the paper was the availability of variables covering 
behaviours over the last month, rather than over a lifetime, meaning they are more directly 
relevant to current practises. However, due to the nature of the questions used to determine 
LDSS use we were only able to include those that had injected in the past month and who had 
recently obtained equipment directly from an NSP, so excluding past and less frequent 
injectors and those not in contact with NSPs. We were also only able to examine injecting 
practices in the past month and were unable to determine how current practices related to 
behaviours when they started injecting. We were also unable to determine when they became 
infected with HCV, which could have been many years ago. Recall bias and social 
desirability considerations may have also impacted on our result, and there were missing data 
for many variables, although we used multiple imputation to account for these missing 
values. Finally, our study is observational and therefore unmeasured confounding may have 
affected our results.  
Implications 
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Our study found a negative association between LDSS use and HCV infection among PWID. 
This possible protective association was particularly strong among those who had initiated 
injecting recently. For determining whether LDSS use reduces the chance of HCV infection it 
is crucial to understand the interaction and effect of groin injecting. There is no doubt that 
groin injecting and HDSS use are highly correlated, but we do not know if groin injecting 
heightens the odds of HCV infection amongst those who use HDSS, or alternatively whether 
groin injecting was a more reliable marker of HDSS use in our survey. Although it is also 
possible that HDSS users may in general have higher odds of HCV infection, with certain 
high-risk markers of HCV (prison and crack injecting) being more prevalent amongst HDSS 
users than LDSS users, it is known that HDSS retain more blood following an injecting 
episode(Binka et al., 2015) and therefore transmit a higher viral load when shared (Abdala et 
al., 1999). This means that using LDSS instead of HDSS is likely to lead to a reduction in 
risk of HCV transmission among PWID that share equipment. 
World Health Organization guidelines on prevention of hepatitis among PWID recommend 
making LDSS available to reduce blood borne infections(World Health Organization, 2012), 
despite there currently being limited direct evidence to support this. Although our study 
supports these guidelines by suggesting LDSS use may be associated with lower odds of 
infection, further research is still needed to obtain stronger evidence on this effect. This 
limitation in the evidence base has no doubt slowed down the expansion of LDSS provision, 
with the availability and use of these syringes varying by region(Ibragimov and Latypov, 
2012). It is encouraging to note that nearly half of our sample used LDSS every time they 
injected in the past month, although over a quarter did not use LDSS. Our study sheds further 
light on who does and does not use LDSS; LDSS use is inversely associated with injecting 
behaviours that are considered more chaotic such as crack injecting, polydrug use, and groin 
injecting(Tweed et al., 2018). The study adds to the evidence that those injecting into deep 
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lying veins, the groin in our study, are a distinct subset of PWID with specific syringe needs 
to enable injection into such sites(Kesten et al., 2017). As previous studies have reported 
injecting into the groin is often considered a last resort once the peripheral veins are no longer 
useable(Hope et al., 2015), resources and information about safer injection practices and 
maintaining better vein health should be used to reduce the extent of injection into the groin, 
and other deep and/or central veins.  
Our study also provides crucial information for interventions aiming to increase the use of 
LDSS amongst PWID, a few of which have recently been initiated(Huong et al., 2015; 
Oramasionwu et al., 2015). LDSS use is highly related to the type of drug used and the body 
site injected into; so to operationalise the World Health Organization guidelines we need 
needles that meet the needs of all PWID while also minimising their dead space. Detachable 
syringes and needles with lower dead space have been developed and are now being 
distributed in some settings. However, although they are an improvement, they still have 
greater dead space than LDSS, resulting in longer survival of HCV within the syringe and 
greater transfer of virus after syringe sharing(Abdala et al., 2016). It is important that further 
syringe development occurs to minimise the dead space associated with these syringes while 
still meeting their need amongst some PWID. 
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Figure 1: Illustrations of the dead space in low and high dead space syringes (artwork 
licensed by Creative Commons). Reproduced with permission from William Zule. 
 
Figure 2: Proportion of PWID with anti-HCV, stratified by number of years since first 
injection and LDSS use percentage 
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Tables 
Tables 1: The demographics and injecting characteristics of PWID for each LDSS use 
category. Results were weighted so N are unavailable. 
Variable 0-99% LDSS use 100% LDSS use Total 
Number (%) 969 (45%) 1,205 (55%) 2,174 (100%) 
Mean (95% confidence 
interval) 
   
Age (years) 38 (37, 38) 37 (36, 37) 37 (37, 37) 
Days injecting † 17 (17, 18) 16 (16, 17) 17 (16, 17) 
Years since first injection 16 (15, 16) 14 (14, 15) 15 (14, 15) 
Number of types of drug 
injected 
1.9 (1.8, 1.9) 1.7 (1.7, 1.8) 1.8 (1.8, 1.8) 
Proportion (95% 
confidence interval) 
   
Women 23% (21%, 26%) 24% (21%, 26%) 24% (22%, 25%) 
Initiated injecting in the past 
3 years 
10% (8%, 12%) 15% (13%, 17%) 13% (11%, 14%) 
Ever been in prison 74% (71%, 77%) 66% (63%, 69%) 70% (68%, 72%) 
Homeless in past year 19% (16%, 21%) 19% (16%, 21%) 19% (17%, 20%) 
Ever injected with received 
needles & syringes 
36% (33%, 39%) 36% (34%, 39%) 36% (34%, 38%) 
Shared equipment † 37% (34%, 40%) 37% (34%, 40%) 37% (35%, 39%) 
Injected into groin † 64% (61%, 67%) 20% (18%, 23%) 40% (38%, 42%) 
Injected with cleaned works† 29% (26%, 32%) 29% (26%, 31%) 29% (27%, 31%) 
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Injected heroin † 90% (88%, 92%) 91% (89%, 93%) 90% (89%, 92%) 
Injected methadone † 2% (1%, 3%) 1% (1%, 2%) 2% (1%, 2%) 
Injected crack † 49% (46%, 52%) 39% (36%, 42%) 43% (41%, 46%) 
Injected cocaine † 9% (7%, 11%) 8% (6%, 9%) 8% (7%, 10%) 
Injected speed † 22% (20%, 25%) 21% (18%, 23%) 21% (20%, 23%) 
Injected ketamine † 2% (1%, 3%) 2% (1%, 3%) 2% (1%, 3%) 
Injected mephedrone † 7% (5%, 8%) 5% (4%, 6%) 6% (5%, 7%) 
Injected other drug † 7% (5%, 8%) 6% (4%, 7%) 6% (5%, 7%) 
 † Past month. Missing data was imputed using multiple imputation. 
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Table 2: The percentage of PWID within each LDSS use category for different geographic 
locations. Results were weighted so N are unavailable. 
Variable 0-99% LDSS use 100% LDSS use Total 
Number (%) 969 (45%) 1,205 (55%) 2,174 (100%) 
Location % of LDSS use category across geographic location  
Total 45% 55% 100% 
London 34% 66% 8% 
East England 51% 49% 7% 
South East 41% 59% 10% 
South West 44% 56% 10% 
West Midlands 32% 68% 8% 
North West 53% 47% 12% 
Yorkshire & Humber 52% 48% 10% 
East Midlands 55% 45% 13% 
North East 39% 61% 8% 
Wales 39% 61% 12% 
Northern Ireland 49% 51% 2% 
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Table 3: Unadjusted and mutually adjusted odds ratios (OR) with 95% confidence intervals 
of 100% LDSS use (against 0-99% LDSS use).  
 
Odds Ratios (95% confidence intervals) of 100% LDSS use 
Variable Unadjusted OR P/wald-value Adjusted OR* P/wald-value Adjusted OR** P/wald-value 
Injected heroin † 1.10 (0.83, 1.47) 0.507 1.47 (1.04, 2.08) 0.028 NA NA 
Injected crack † 0.67 (0.57, 0.80) <0.001 0.79 (0.63, 0.98) 0.032 NA NA 
Injected other drug † 0.80 (0.56, 1.14) 0.226 0.63 (0.42, 0.95) 0.028 NA NA 
Injected into groin † 0.14 (0.12, 0.17) <0.001 0.14 (0.11, 0.17) <0.001 0.14 (0.12, 0.17) <0.001 
No. of types of drug 
injected (per drug) † 
0.81 (0.74, 0.90) <0.001 NA NA 0.88 (0.79, 0.98) 0.024 
       
London 1  1  1  
East England 0.49 (0.31, 0.77) 0.002 0.50 (0.30, 0.83) 0.007 0.51 (0.31, 0.84) 0.008 
South East 0.73 (0.48, 1.10) 0.131 0.95 (0.60, 1.50) 0.823 0.94 (0.60, 1.50) 0.806 
South West 0.63 (0.42, 0.96) 0.030 0.85 (0.54, 1.35) 0.497 0.81 (0.51, 1.29) 0.374 
West Midlands 1.05 (0.67, 1.64) 0.821 1.16 (0.70, 1.91) 0.565 1.17 (0.71, 1.92) 0.538 
North West 0.45 (0.30, 0.67) <0.001 0.60 (0.38, 0.94) 0.024 0.59 (0.38, 0.92) 0.020 
Yorkshire 0.47 (0.31, 0.71) <0.001 0.64 (0.40, 1.02) 0.059 0.64 (0.41, 1.01) 0.056 
East Midlands 0.42 (0.28, 0.62) <0.001 0.48 (0.31, 0.75) 0.001 0.48 (0.31, 0.74) 0.001 
North East 0.78 (0.51, 1.21) 0.268 0.89 (0.54, 1.46) 0.637 0.93 (0.57, 1.51) 0.761 
Wales 0.80 (0.54, 1.20) 0.289 1.01 (0.64, 1.60) 0.974 1.03 (0.66, 1.60) 0.913 
Northern Ireland 0.53 (0.27, 1.02) 0.058 0.44 (0.21, 0.93) 0.031 0.45 (0.22, 0.92) 0.030 
Days injecting† 0.99 (0.98, 1.00) 0.018 NA    
Age (years) 0.99 (0.98, 1.00) 0.009 NA    
Years since first 
injection 
0.98 (0.97, 0.99) <0.001 NA    
Injected methadone † 0.68 (0.36, 1.28) 0.234 NA    
Injected cocaine † 0.80 (0.59, 1.09) 0.152 NA    
Injected speed † 0.90 (0.73, 1.10) 0.298 NA    
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Injected ketamine † 1.06 (0.58, 1.94) 0.853 NA    
Injected mephedrone 
† 
0.72 (0.49, 1.05) 0.084 NA    
Homeless last year 1.00 (0.80, 1.24) 0.989 NA    
Female 1.01 (0.83, 1.24) 0.924 NA    
Ever injected with 
received needles & 
syringes 
1.00 (0.84, 1.20) 0.966 NA    
Reported sharing 
injecting equipment † 
1.00 (0.84, 1.19) 0.993 NA    
Ever imprisoned  0.69 (0.57, 0.83) <0.001 NA    
† Past month 
*The adjusted OR were adjusted for variables selected in the multivariable model which did 
not include number of types of drug injected.  
**The adjusted OR for number of types of drug was adjusted for geographical location and 
groin injecting and not for heroin, crack, or other drug. 
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Table 4: Odds ratios (OR) of being anti-HCV positive (i) unadjusted, (ii) adjusted – with the 
percentage of the sample in each category, and the percentage of each group with HCV 
infection. N=2,174.  
Variable %  % HCV +ve Unadjusted OR  Adjusted OR 
0-99% LDSS use 45% 61% 1 1 
100% LDSS use 55% 50% 0.64 (0.54, 0.76) 0.77 (0.64, 0.93) 
Adjusted for the following variables: Injections (every 10) per month, shared equipment last 
month, years since first injection, injecting crack, injecting heroin, injecting “other drug”, 
ever been in prison, and homeless in the last year.  
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Table 5: Odds ratios (OR) of being anti-HCV positive, including an interaction term between 
LDSS use and having started injecting during the last 3 years. Table 5a shows the interaction 
using 0-99% LDSS users who are recent starters as the comparator group, whilst for Table 5b 
the comparator is 0-99% LDSS users who are non-recent starters.  
(a) Variable 
% % HCV 
+ve Unadjusted OR Adjusted OR 
0-99% LDSS use & recent starter 5% 35% 1 1 
100% LDSS use & recent starter 8% 20% 0.46 (0.26, 0.80) 0.53 (0.30, 0.94) 
(b) Variable 
% % HCV 
+ve Unadjusted OR Adjusted OR 
0-99% LDSS use & non-recent starter 40% 64% 1 1 
100% LDSS use & non-recent starter 47% 55% 0.70 (0.58, 0.85) 0.81 (0.66, 0.99) 
Adjusted for the following variables: Injections (every 10) per month, shared equipment past 
month, years since first injection, injecting crack, injecting heroin, injecting “other drug”, and 
ever been in prison, and homeless in the past year. N=2,174. 
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Supplementary table 1: The adjusted Odds Ratios with 95% confidence intervals of 100% 
LDSS use (against 0-99% LDSS use) produced from a logistic regression model using 
backwards stepwise selection on each of the five imputed datasets.  
  
Backwards Stepwise Logistic Regression, Adjusted Odds Ratios (95% Confidence 
Interval) 
Variable Imputed set 1 Imputed set 2 Imputed set 3 Imputed set 4 Imputed set 5 
Location 
     
London 1 1 1 1 1 
East England 0.51 (0.31, 0.85) 0.50 (0.31, 0.83) 0.51 (0.31, 0.85) 0.52 (0.32, 0.86) 0.51 (0.31, 0.84) 
South East 0.96 (0.61, 1.52) 0.93 (0.59, 1.48) 0.95 (0.60, 1.51) 0.97 (0.61, 1.54) 0.94 (0.59, 1.49) 
South West 0.84 (0.53, 1.34) 0.86 (0.54, 1.37) 0.87 (0.55, 1.38) 0.89 (0.56, 1.41) 0.85 (0.54, 1.36) 
West Midlands 1.14 (0.69, 1.87) 1.14 (0.69, 1.87) 1.14 (0.69, 1.88) 1.19 (0.72, 1.98) 1.13 (0.69, 1.87) 
North West 0.60 (0.39, 0.94) 0.61 (0.39, 0.95) 0.59 (0.38, 0.93) 0.63 (0.40, 0.98) 0.60 (0.38, 0.94) 
Yorkshire 0.62 (0.39, 0.98) 0.62 (0.39, 0.99) 0.62 (0.39, 0.99) 0.65 (0.41, 1.04) 0.62 (0.39, 0.99) 
East Midlands 0.46 (0.30, 0.72) 0.47 (0.30, 0.73) 0.50 (0.30, 0.73) 0.49 (0.31, 0.77) 0.46 (0.30, 0.72) 
North East 0.86 (0.52, 1.42) 0.85 (0.52, 1.41) 0.87 (0.52, 1.43) 0.93 (0.56, 1.55) 0.86 (0.52, 1.42) 
Wales 1.00 (0.63, 1.58) 1.00 (0.63, 1.58) 1.01 (0.64, 1.60) 1.05 (0.66, 1.68) 1.00 (0.63, 1.59) 
Northern Ireland 0.41 (0.20, 0.87) 0.42 (0.20, 0.88) 0.42 (0.20, 0.89) 0.43 (0.20, 0.90) 0.41 (0.20, 0.87) 
Previous study 
participation 1.25 (0.98, 1.60) 1.20 (0.94, 1.53) 1.26 (0.99, 1.61) 1.22 (0.96, 1.56) 1.21 (0.95, 1.54) 
Born in the UK Not Included Not Included Not included 0.73 (0.47, 1.15) Not Included 
Groin injector 0.14 (0.11, 0.17) 0.14 (0.11, 0.17) 0.14 (0.11, 0.17) 0.14 (0.11, 0.17) 0.14 (0.11, 0.17) 
Injected crack 0.79 (0.63, 0.98) 0.77 (0.62, 0.96) 0.80 (0.64, 0.99) 0.79 (0.64, 0.98) 0.78 (0.63, 0.98) 
Injected heroin 1.46 (1.04, 2.05) 1.44 (1.03, 2.02) 1.53 (1.09, 2.15) 1.45 (1.04, 2.03) 1.54 (1.10, 2.17) 
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Injected other 0.64 (0.43, 0.96) 0.63 (0.42, 0.88) 0.63 (0.42, 0.94) 0.63 (0.42, 0.95) 0.66 (0.44, 0.98) 
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Supplementary table 2: Odds ratios (OR) of being anti-HCV positive (against negative) (i) 
unadjusted, (ii) adjusted. N=2,174. 
Variable Unadjusted Adjusted 
0-99% LDSS use 1 1 
100% LDSS use 0.64 (0.54, 0.76) 0.77 (0.64, 0.93) 
   
Injections (every 10) per 
month 1.11 (0.92, 1.33) 1.10 (0.90, 1.35) 
Shared equipment last month 1.22 (1.01, 1.46) 1.28 (1.05, 1.56) 
Years since first injection 1.08 (1.07, 1.09) 1.07 (1.06, 1.08) 
Injecting crack 2.58 (2.15, 3.09) 2.23 (1.83, 2.71) 
Injecting heroin 1.67 (1.24, 2.24) 1.20 (0.86, 1.67) 
Injecting “other drug” 0.77 (0.54, 1.11) 0.78 (0.53, 1.17) 
Injecting into groin 2.35 (1.96, 2.81) NA 
Ever been in prison 2.83 (2.34, 3.42) 2.11 (1.72, 2.59) 
Homeless in last year 1.18 (0.95, 1.47) 1.23 (0.97, 1.57) 
Groin injecting was not included in the adjusted model as syringe type was on the causal 
pathway between groin injecting and HCV. 
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Supplementary table 3: Odds ratios (OR) of being anti-HCV positive (against negative), 
including an interaction term between LDSS use and having started injecting during the last 3 
years (i) unadjusted, (ii) adjusted. N=2,174. 
Variable Unadjusted Adjusted 
0-99% LDSS use & recent starter 1 1 
100% LDSS use & recent starter 0.46 (0.26, 0.80) 0.53 (0.30, 0.94) 
0-99% LDSS use & non-recent starter 3.23 (2.08, 5.02) 1.23 (0.75, 2.04) 
100% LDSS use & non-recent starter 2.27 (1.47, 3.51) 1.00 (0.61, 1.63) 
   
Injections (every 10) per month 1.11 (0.92, 1.33) 1.10 (0.90, 1.35) 
Shared equipment last month 1.22 (1.01, 1.46) 1.29 (1.06, 1.58) 
Years since first injection 1.08 (1.07, 1.09) 1.06 (1.05, 1.08) 
Injecting crack 2.58 (2.15, 3.09) 2.26 (1.85, 2.76) 
Injecting heroin 1.67 (1.24, 2.24) 1.17 (0.84, 1.64) 
Injecting “other drug” 0.77 (0.54, 1.11) 0.78 (0.52, 1.17) 
Injecting into groin 2.35 (1.96, 2.81) NA 
Ever been in prison 2.83 (2.34, 3.42) 2.07 (1.68, 2.54) 
Homeless in last year 1.18 (0.95, 1.47) 1.24 (0.97, 1.58) 
Groin injecting was not included in the adjusted model as syringe type was on the causal 
pathway between groin injecting and HCV. 
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Supplementary figure 1: The proportion of PWID in each LDSS use category, stratified by 
number of years since first injection. 
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Supplementary figure 2: The adjusted Odds Ratios of anti-HCV positivity, for 100% LDSS 
use (versus 0%-99% LDSS use) amongst PWID that have recently started injecting, varied by 
the threshold (number of years) used to define recent initiation of injecting. This figure shows 
the bolded result in the adjusted column of supplementary table 3, using different definitions 
of having recently started injecting. 
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